1 / 48

Pheochromocytoma

Pheochromocytoma. Dr. Atallah Al- Ruhaily. Pheochromocytoma. Catecholamine Physiology/Pathophysiology Clinical Presentation Epidemiology Signs & Symptoms Diagnosis Biochemical Localization Management Preoperative Operative Postoperative Pregnancy. Catecholamine Producing Tumors.

sonora
Download Presentation

Pheochromocytoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pheochromocytoma Dr. Atallah Al-Ruhaily

  2. Pheochromocytoma • Catecholamine Physiology/Pathophysiology • Clinical Presentation • Epidemiology • Signs & Symptoms • Diagnosis • Biochemical • Localization • Management • Preoperative • Operative • Postoperative • Pregnancy

  3. Catecholamine Producing Tumors Neural Crest Neuroblastoma Sympathoadrenal Progenitor Cell (Neuroblasts) Chromaffin Cell Sympathetic Ganglion Cell Intra-adrenal Extra-adrenal Pheochromocytoma Ganglioneuroma

  4. Catecholamine Producing Tumors • Pheochromocytoma • Paraganglioma (extra-adrenal pheo) • Originate in extra-adrenal sympathetic chain/chromaffintissue • Ganglioneuroma • Behave like paragangliomabiochemically

  5. Catecholamine Producing Tumors • Neuroblastoma • Common malignancy in children, adrenal or sympathetic chain • Catecholamine humoral effects usually minor • Rapid growth & widespread metastasis • Some differentiate and spontaneously regress • Rx complex (surgery, XRT, chemotherapy) • Cheodectoma • Carotid body, behave like paragangliomabiochemically • Glomusjugulare tumor • Intracranial branch of CN IX and X • Behave like paragangliomoa biochemically

  6. Catecholamines Metabolites MAO, COMT TH Tyrosine L-Dopa Dopamine Homovanillic acid (HVA) DBH COMT Norepinephrine Normetanephrine PNMT MAO COMT Epinephrine Metaneprine • Tumor Secretion: • Large Pheo: more metabolites • (metabolized within tumor before release) • Small Pheo: more catecholamines • Sporadic Pheo:Norepi > Epi • Familial Pheo:Epi > Norepi • Paraganglioma:Norepi • Cheodectoma, glomusjugulare:Norepi • Gangioneuroma:Norepi • Malignant Pheo: Dopamine, HVA • Neuroblastoma: Dopamine, HVA MAO Vanillymandelic Acid (VMA) • PNMT: Phenylethanolamine-N-Methyl Transferase • COMT : Catechol-O-Methyl Ttransferase • MAO: Mono-Amine Oxidase

  7. Adrenergic Receptors • Alpha-Adrenergic Receptors • 1:vasoconstriction, intestinal relaxation, uterine contraction, pupillary dilation • 2:  presynaptic NE (clonidine), platelet aggregation, vasoconstriction,  insulin secretion • Beta-Adrenergic Receptors • 1:  HR/contractility,  lipolysis,  renin secretion • 2:vasodilation, bronchodilation,  glycogenolysis • 3:  lipolysis,  brown fat thermogenesis

  8. Pheochromocytoma • Catecholamine Physiology/Pathophysiology • Clinical Presentation • Epidemiology • Signs & Symptoms • Diagnosis • Biochemical • Localization • Management • Preoperative • Operative • Postoperative • Pregnancy

  9. Pheochromocytoma • 0.01-0.1% of HTN population • Found in 0.5% of those screened • M = F • 3rd to 5th decades of life • Rare, investigate only if clinically suspicion: • Signs or Symptoms • Severe HTN, HTN crisis • Refractory HTN (> 3 drugs) • HTN present @ age < 20 or > 50 ? • Adrenal lesion found on imaging (ex. Incidentaloma)

  10. Pheo: Signs & Symptoms • The five P’s: • Pressure (HTN) 90% • Pain (Headache) 80% • Perspiration 71% • Palpitation 64% • Pallor 42% • Paroxysms • The Classical Triad: • Pain (Headache), Perspiration, Palpitations • Lack of all 3 virtually excluded diagnosis of pheo in a series of > 21,0000 patients

  11. Pheo: Paroxysms, ‘Spells’ • 10-60 min duration • Frequency: daily to monthly • Spontaneous • Precipitated: • Diagnostic procedures, I.A. Contrast (I.V. is OK) • Drugs (opiods, unopposed -blockade, anesthesia induction, histamine, ACTH, glucagon, metoclopramide) • Strenuous exercise, movement that increases intra-abdo pressure (lifting, straining) • Micturition (bladder paraganlgioma)

  12. Pheo: Hypotension! • Hypotension (orthostatic/paroxysmal) occurs in many patients • Mechanisms: • ECFv contraction • Loss of postural reflexes due to prolonged catecholamine stimulation • Tumor release of adrenomedullin (vasodilatory neuropeptide)

  13. Pheo: Signs & Symptoms • N/V, abdo pain, severe constipation (megacolon) • Chest-pains • Anxiety • Angina/MI with normal coronaries: • Catecholamine induced:  myocardial oxygen consumption or coronary vasospasm • CHF • HTN  hypertrophic cardiomyopathy  diastolic dysfn. • Catechols induce dilated cardiomyopathy  systolic dysfn. • Cardiac dysrhythmia & conduction defects

  14. Pheo: Signs (metabolic) • Hypercalcemia • Associated MEN2 HPT • PTHrP secretion by pheo • Mild glucose intolerance • Lipolysis • Weight-loss • Ketosis > VLDL synthesis (TG)

  15. Pheo: ‘Rule of 10’ • 10% extra-adrenal (closer to 15%) • 10% occur in children • 10% familial (closer to 20%) • 10% bilateral or multiple (more if familial) • 10% recur (more if extra-adrenal) • 10% malignant • 10% discovered incidentally

  16. Familial Pheo • MEN 2a • 50% Pheo (usually bilateral), MTC, HPT • MEN 2b • 50% Pheo (usually bilatl), MTC, mucosal neuroma, marfanoid habitus • Von Hippel-Landau • 50% Pheo (usually bilat), retinoblastoma, cerebellar hemangioma, nephroma, renal/pancreas cysts • NF1 (Von Recklinghausen's) • 2% Pheo (50% if NF-1 and HTN) • Café-au-lait spots, neurofibroma, optic glioma • Familial paraganglioma • Familial pheo & islet cell tumor • Other: Tuberous sclerosis, Sturge-Weber, ataxia-telangectgasia, Carney’s Triad (Pheo, Gastric Leiomyoma, Pulm chondroma)

  17. Pheochromocytoma • Catecholamine Physiology/Pathophysiology • Clinical Presentation • Epidemiology • Signs & Symptoms • Diagnosis • Biochemical • Localization • Management • Preoperative • Operative • Postoperative • Pregnancy

  18. 24h Urine Collection • 24h urine collection: • Creatinine, catecholamines, metanephrines, vanillymandelic acid (VMA), +/-dopamine • HPLC with electrochemical detection or mass spect • Positive results (> 2-3 fold elevation): • 24h Ucatechols > 2-fold elevation • ULN for total catechols 591-890 nmol/d • 24h Utotal metanephrines > 1.2 ug/d (6.5 umol/d) • 24h UVMA > 3-fold elevation • ULN 35 umol/d for most assays

  19. 24h Urine Collection • Test Characteristics: • 24h Ucatechols Sen 83% Spec 88% • 24h Utotal metanephrines Sen 76% Spec 94% • 24h Ucatechols + Utotal metanephrines Sen 90% Spec 98% • 24h UVMA Sen 63% Spec 94% • Sensitivity increased if 24h urine collection begun at onset of a paroxysm

  20. 24h Urine: False Positive • Drugs: TCAs, MAO-i, levodopa, methyldopa, labetalol, propanolol, clonidine (withdrawal), ilicit drugs (opiods, amphetamines, cocaine), ethanol, sympathomimetics (cold remedies) • Hold these medications for 2 weeks! • Major physical stress (hypoglycemia, stroke, raised ICP, etc.) • OSA

  21. Plasma Catecholamines • Drawn with patient fasting, supine, with an indwelling catheter in place > 30 min • Plasma total catechols > 11.8 nM (2000 pg/mL) • SEN 85% SPEC 80% • False positives: same as for 24h urine testing, also with diuretics, smoking • CRF & ESRD: • Oliguric to Anuric  24h Urines inaccurate • Plasma epinephrine best test for pheo in ESRD • Plasma norepi and metanephrines falsely elevated in ESRD

  22. Plasma Metanephrines • Not postural dependent: can draw normally • Secreted continuously by pheo • SEN 99% SPEC 89% • False Positive: acetaminophen

  23. Biochemical Tests: Summary

  24. Suppression/Stimulation Testing • Clonidine suppression • May precipitate hypotensive shock! • Unlike normals, pheo patients won’t suppress their plasma norepi with clonidine • Glucagon stimulation • May precipitate hypertensive crisis! • Pheo patients, but not normals, will have a > 3x increase in plasma norepi with glucagon

  25. Localization: Imaging • CT abdomen • Adrenal pheo SEN 93-100% • Extra-adrenal pheo SEN 90% • MRI • > SEN than CT for extra-adrenal pheo

  26. Localization: Imaging • CT abdomen • Adrenal pheo SEN 93-100% • Extra-adrenal pheo SEN 90% • MRI • > SEN than CT for extra-adrenal pheo • MIBG Scan • SEN 77-90% SPEC 95-100%

  27. MIBG Scan • 123I or 131I labelled metaiodobenzylguanidine • MIBG catecholamine precurosr taken up by the tumor • Inject MIBG, scan @ 24h, 48h, 72h • Lugol’s 1 gtt tid x 9d (from 2d prior until 7d after MIBG injection to protect thyroid) • False negative scan: • Drugs: Labetalol, reserpine, TCAs, phenothiazines • Must hold these medications for 4-6 wk prior to scan

  28. Localization: Nuclear medicine • MIBG • 111Indium-pentreotide • Some pheo have somatostatin receptors • PET • 18F-fluorodeoxyglucose (FDG) • 6-[18F]-fluorodopamine

  29. Pheochromocytoma • Catecholamine Physiology/Pathophysiology • Clinical Presentation • Epidemiology • Signs & Symptoms • Diagnosis • Biochemical • Localization • Management • Preoperative • Operative • Postoperative • Pregnancy

  30. Pheo Management • Prior to 1951, reported mortality for excision of pheochromoyctoma 24 - 50 % • HTN crisis, arrhythmia, MI, stroke • Hypotensive shock • Currently, mortality:0 - 2.7 % • Preoperative preperation, -blockade? • New anesthetic techniques? • Anesthetic agents • Intraoperative monitoring: arterial line, EKG monitor, CVP line, Swan-Ganz • Experienced & Coordinated team: • Endocrinologist, Anesthesiologist and Surgeon

  31. Preop W/up • CBC, lytes, creatinine, INR/PTT • CXR • EKG • Echo (r/o dilated CMY 2º catechols)

  32. Preop Preperation Regimens • Combined  +  blockade • Phenoxybenzamine • Selective 1-blocker (ex. Prazosin) • Propanolol • Metyrosine • Calcium Channel Blocker (CCB) • Nicardipine

  33. Preop:  +  blockade • Start at least 10-14d preop • Allow sufficient time for ECFv re-expansion • Phenoxybenzamine • Special pharmacy access only (no DIN) • Drug of choice • Covalently binds -receptors (1 > 2) • Start 10 mg po bid  increase q2d by 10-20 mg/d • Increase until BP cntrl and no more paroxysms • Maintenance 40-80 mg/d (some need > 200 mg/d) • Salt load: NaCl 600 mg od-tid as tolerated

  34. Preop:  +  blockade • Phenoxybenzamine (cont’d) • Side-effect: orthostasis with dosage required to normalized seated BP, reflex tachycardia • Drawback: periop hypotension/shock unlikely to respond to pressor agent. • Selective 1-blockers • Prazosin, Terazosin, Doxazosin • Some experience with Prazosin for Pheo preop prep • Not routinely used as incomplete-blockade • Less orthostasis & reflex tachycardia then phenoxybenzamine • Used more for long-term Rx (inoperable or malignant pheo)

  35. Preop:  +  blockade • -blockade • Used to control reflex tachycardia and prophylaxis against arrhythmia during surgery • Start only after effective -blockade (may ppt HTN) • If suspect CHF/dilated CMY  start low dose • Propanolol most studied in pheo prep • Start 10 mg po bid  increase to cntrl HR

  36. Preop:  +  blockade • If BP still not cntrl despite  +  blockade • Add Prazosin to Phenoxybenzamine • Add CCB, ACE-I • Avoid diuretics as already ECFv contracted • Metyrosine

  37. Preop:  +  blockade • Meds given on AM of surgery • Periop HTN: • IV phentolamine • Short acting non-selective -blocker • Test dose 1 mg, then 2-5 mg IV q1-2h PRN or as continuous infusion (100 mg in 500cc D5W, titrate to BP) • IV Nitroprusside (NTP) • Periop arrhythmia: IV esmolol • Periop Hypothension: IV crystalloid +/- colloid

  38. Pheo: Rx of HTN Crisis • IV phentolamine • IV NTP • IV esmolol • IV labetalol – combined  +  blocker

  39. Preop: Metyrosine TH Tyrosine L-Dopa Dopamine • Synthetic inhibitor of Tyrosine Hydroxylase (TH) • Special pharm access, no DIN • Start 250 mg qid  max 1 gm qid • Severe S/E’s: sedation, extrapyramidal, diarrhea, nausea/vomit, anxiety, renal/chole stones, galactorrhea • Alone may insufficiently cntrl BP and reported HTN crises during pheo operation • Restrict use to inoperable/malignant pheo or as adjunct to  +  blockade or other preop prep DBH Norepinephrine PNMT Epinephrine

  40. Preop: CCB • CCB • Block norepi mediated Ca transport into vascular smooth muscle • Nicardipine: most commonly used agent • Nicardipine (France Study) • Started po 24h to few weeks preop to cntrl BP and allow ECFv restoration • After intubation  IV Nicardipinegtt (start 2.5 ug/kg/min) • IV Nicardipine adjusted to SBP • Stopped prior to ligation of tumor venous drainage • Tachycardia Rx with concurrent IV esmolol • Advantage:periop hypotension may still respond to pressor agents as opposed to those patients who are completely -blocked

  41. O.R. • Admit night before for overnight IV saline • Arterial line, EKG monitor, CVP line • Known CHF: consider Swan-Ganz • Regardless of preop medications: • Have ready: IV phentolamine, IV NTP, IV esmolol • Rx hypotension with crystalloid +/- colloid 1st • Aim for CVP 12 or Wedge 15 • Inotropes may not work!

  42. O.R. • Anesthetic choice: • Enflurane or isoflurane: don’t sensitized myocardium to catecholamines • Halothane: may sensitize heart  arrhythmia • Laprascopic adrenalectomy if tumor < 8cm

  43. Postop • Most cases can stop all BP meds postop • Postop hypotension: IV crystalloid • HTN free: 5 years 74% 10 years 45% • 24h urine collection 2 wk postop • Surveillance: • 24h urine collections q1y for at least 10y • Lifelong f/up

  44. Pheo: Unresectable, Malignant • -blockade • Selective 1-blockers (Prazosin, Terazosin, Doxazosin) 1st line as less side-effects • Phenoxybenzamine: more complete -blockade • -blocker • CCB, ACE-I, etc. • Nuclear Medicine Rx: • Hi dose 131I-MIBG or 111indium-octreotide depending on MIBG scan or octreoscan pick-up • Sensitize tumor with Carboplatin + 5-FU

  45. Pheo & Pregnancy • Diagnosis with 24h urine collections and MRI • No stimulation tests, no MIBG if pregnant • 1st & 2nd trimester (< 24 weeks): • Phenoxybenzamine + blocker prep • Resect tumor ASAP laprascopically • 3rd trimester: • Phenoxybenzamine + blocker prep • When fetus large enough: cesarian section followed by tumor resection

More Related